InfuSystem Holdings, Inc. (NYSE:INFU) Director Kenneth D. Eichenbaum Buys 4,000 Shares

InfuSystem Holdings, Inc. (NYSE:INFU) Director Kenneth D. Eichenbaum purchased 4,000 shares of InfuSystem stock in a transaction dated Monday, September 23rd. The shares were bought at an average cost of $5.89 per share, for a total transaction of $23,560.00. Following the transaction, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $23,560. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

InfuSystem Stock Up 2.9 %

NYSE INFU opened at $6.75 on Friday. The stock has a market capitalization of $143.74 million, a PE ratio of -675,000.00 and a beta of 1.46. InfuSystem Holdings, Inc. has a one year low of $5.74 and a one year high of $10.99. The company has a quick ratio of 1.64, a current ratio of 2.07 and a debt-to-equity ratio of 0.64.

InfuSystem (NYSE:INFU) last posted its earnings results on Thursday, August 8th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.01). The company had revenue of $33.70 million for the quarter. InfuSystem had a net margin of 0.28% and a return on equity of 0.70%.

Wall Street Analyst Weigh In

INFU has been the topic of several research reports. StockNews.com cut InfuSystem from a “strong-buy” rating to a “buy” rating in a research note on Saturday. B. Riley started coverage on InfuSystem in a research report on Thursday. They set a “buy” rating and a $13.00 price target on the stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in INFU. Vanguard Group Inc. boosted its holdings in shares of InfuSystem by 1.7% during the first quarter. Vanguard Group Inc. now owns 1,083,730 shares of the company’s stock valued at $9,288,000 after acquiring an additional 18,432 shares during the period. Wasatch Advisors LP lifted its position in InfuSystem by 3.4% in the 4th quarter. Wasatch Advisors LP now owns 846,609 shares of the company’s stock valued at $8,923,000 after purchasing an additional 27,881 shares during the last quarter. Ranger Investment Management L.P. boosted its stake in InfuSystem by 4.7% during the 4th quarter. Ranger Investment Management L.P. now owns 689,842 shares of the company’s stock valued at $7,271,000 after purchasing an additional 30,835 shares during the period. First Eagle Investment Management LLC grew its position in InfuSystem by 10.0% in the 2nd quarter. First Eagle Investment Management LLC now owns 666,048 shares of the company’s stock worth $4,549,000 after purchasing an additional 60,813 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of InfuSystem by 6.1% in the second quarter. Bank of New York Mellon Corp now owns 93,899 shares of the company’s stock valued at $641,000 after purchasing an additional 5,391 shares during the period. 71.13% of the stock is currently owned by institutional investors.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.